Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough.

[2][3][4] It was approved for medical use in the European Union in September 2023.

[1] Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.

[1] It was named in honour of Geoff Burnstock.

This drug article relating to the respiratory system is a stub.